Do analysts rate DCOY or ANEB?

Decoy Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Decoy Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable earnings & valuation, DCOY or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is DCOY or ANEB more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -395.42% -193.30% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Does the media prefer DCOY or ANEB?

In the previous week, Decoy Therapeutics had 4 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 5 mentions for Decoy Therapeutics and 1 mentions for Anebulo Pharmaceuticals. Decoy Therapeutics' average media sentiment score of 0.22 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Decoy Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anebulo Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, CALC or DCOY?

CalciMedica is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CalciMedica N/A N/A -$29.56M -$1.31 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is CALC or DCOY more profitable?

Decoy Therapeutics' return on equity of -395.42% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% Decoy Therapeutics N/A -395.42% -193.30%

Does the media favor CALC or DCOY?

In the previous week, Decoy Therapeutics had 2 more articles in the media than CalciMedica. MarketBeat recorded 5 mentions for Decoy Therapeutics and 3 mentions for CalciMedica. CalciMedica's average media sentiment score of 1.51 beat Decoy Therapeutics' score of 0.22 indicating that CalciMedica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Decoy Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, PASG or DCOY?

Passage Bio is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is PASG or DCOY more profitable?

Passage Bio's return on equity of -150.88% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Decoy Therapeutics N/A -395.42% -193.30%

Does the media favor PASG or DCOY?

In the previous week, Decoy Therapeutics had 2 more articles in the media than Passage Bio. MarketBeat recorded 5 mentions for Decoy Therapeutics and 3 mentions for Passage Bio. Passage Bio's average media sentiment score of 1.51 beat Decoy Therapeutics' score of 0.22 indicating that Passage Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Decoy Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DCOY or NAII?

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Decoy Therapeutics is more favorable than Natural Alternatives International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate DCOY or CYCN?

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Decoy Therapeutics (DCOY) Competitors

$7.31 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$6.94 -0.36 (-4.99%)

As of 07/2/2026 07:53 PM Eastern

Compare

DCOY vs. ANEB, CALC, PASG, NAII, and CYCN

Should you buy Decoy Therapeutics stock or one of its competitors? MarketBeat compares Decoy Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Decoy Therapeutics include Anebulo Pharmaceuticals (ANEB), CalciMedica (CALC), Passage Bio (PASG), Natural Alternatives International (NAII), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry.

How does Decoy Therapeutics compare to Anebulo Pharmaceuticals?

Decoy Therapeutics (NASDAQ:DCOY) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 1.7% of Decoy Therapeutics shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Anebulo Pharmaceuticals' return on equity of -74.57% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Decoy Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Decoy Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Decoy Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.83, indicating that its share price is 283% less volatile than the broader market.

In the previous week, Decoy Therapeutics had 4 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 5 mentions for Decoy Therapeutics and 1 mentions for Anebulo Pharmaceuticals. Decoy Therapeutics' average media sentiment score of 0.22 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Decoy Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anebulo Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Decoy Therapeutics beats Anebulo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Decoy Therapeutics compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

11.9% of Decoy Therapeutics shares are owned by institutional investors. 41.5% of CalciMedica shares are owned by company insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Decoy Therapeutics' return on equity of -395.42% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
Decoy Therapeutics	N/A	-395.42%	-193.30%

CalciMedica presently has a consensus price target of $10.00, indicating a potential upside of 935.84%. Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 310.40%. Given CalciMedica's higher probable upside, equities research analysts plainly believe CalciMedica is more favorable than Decoy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CalciMedica has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

CalciMedica is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

In the previous week, Decoy Therapeutics had 2 more articles in the media than CalciMedica. MarketBeat recorded 5 mentions for Decoy Therapeutics and 3 mentions for CalciMedica. CalciMedica's average media sentiment score of 1.51 beat Decoy Therapeutics' score of 0.22 indicating that CalciMedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Decoy Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CalciMedica beats Decoy Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Decoy Therapeutics compare to Passage Bio?

Passage Bio (NASDAQ:PASG) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Decoy Therapeutics had 2 more articles in the media than Passage Bio. MarketBeat recorded 5 mentions for Decoy Therapeutics and 3 mentions for Passage Bio. Passage Bio's average media sentiment score of 1.51 beat Decoy Therapeutics' score of 0.22 indicating that Passage Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Decoy Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Passage Bio has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 1.7% of Decoy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Passage Bio is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Passage Bio currently has a consensus price target of $13.25, suggesting a potential upside of 183.12%. Decoy Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 310.40%. Given Decoy Therapeutics' higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Passage Bio's return on equity of -150.88% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Decoy Therapeutics	N/A	-395.42%	-193.30%

Summary

Passage Bio beats Decoy Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Decoy Therapeutics compare to Natural Alternatives International?

Decoy Therapeutics (NASDAQ:DCOY) and Natural Alternatives International (NASDAQ:NAII) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Decoy Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Natural Alternatives International	-10.13%	-12.21%	-5.30%

In the previous week, Decoy Therapeutics had 5 more articles in the media than Natural Alternatives International. MarketBeat recorded 5 mentions for Decoy Therapeutics and 0 mentions for Natural Alternatives International. Decoy Therapeutics' average media sentiment score of 0.22 beat Natural Alternatives International's score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Natural Alternatives International	Neutral

Decoy Therapeutics has higher earnings, but lower revenue than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Natural Alternatives International	$129.86M	0.11	-$13.57M	-$2.39	N/A

Decoy Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are owned by institutional investors. 1.7% of Decoy Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Natural Alternatives International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Decoy Therapeutics is more favorable than Natural Alternatives International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Decoy Therapeutics beats Natural Alternatives International on 9 of the 15 factors compared between the two stocks.

How does Decoy Therapeutics compare to Cyclerion Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Decoy Therapeutics has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -62.10% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Cyclerion Therapeutics	-170.11%	-62.10%	-55.14%

In the previous week, Decoy Therapeutics had 5 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 5 mentions for Decoy Therapeutics and 0 mentions for Cyclerion Therapeutics. Decoy Therapeutics' average media sentiment score of 0.22 beat Cyclerion Therapeutics' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Cyclerion Therapeutics	Neutral

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 1.7% of Decoy Therapeutics shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cyclerion Therapeutics has higher revenue and earnings than Decoy Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Cyclerion Therapeutics	$2.07M	7.17	-$3.53M	-$1.36	N/A

Decoy Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

Summary

Cyclerion Therapeutics beats Decoy Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Decoy Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCOY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCOY vs. The Competition

Export

Metric	Decoy Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.89M	$791.45M	$5.20B	$12.48B
Dividend Yield	N/A	4.84%	16.11%	6.52%
P/E Ratio	-0.07	1.66	23.91	24.70
Price / Sales	N/A	127.11	216.83	99.42
Price / Cash	N/A	20.06	35.06	57.09
Price / Book	0.66	8.17	13.25	6.46
Net Income	-$12.52M	-$3.71M	$113.80M	$337.01M
7 Day Performance	32.43%	2.59%	0.93%	1.69%
1 Month Performance	10.59%	4.41%	1.08%	3.81%
1 Year Performance	N/A	49.43%	10.03%	23.90%

Decoy Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCOY Decoy Therapeutics	3.0473 of 5 stars	$7.31 flat	$30.00 +310.4%	N/A	$3.89M	N/A	N/A	20	Gap Down
ANEB Anebulo Pharmaceuticals	0.0378 of 5 stars	$0.38 flat	N/A	-77.7%	$15.50M	N/A	N/A	4
CALC CalciMedica	3.5193 of 5 stars	$0.97 flat	$10.00 +935.8%	-40.4%	$15.25M	N/A	N/A	30	Positive News Short Interest Increase Gap Up
PASG Passage Bio	4.7051 of 5 stars	$4.68 flat	$13.25 +183.1%	-49.2%	$15.01M	N/A	N/A	130	Positive News
NAII Natural Alternatives International	0.9621 of 5 stars	$2.37 flat	N/A	-26.2%	$14.87M	$141.87M	N/A	290	Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCOY) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Decoy Therapeutics (DCOY) Competitors

DCOY vs. ANEB, CALC, PASG, NAII, and CYCN

How does Decoy Therapeutics compare to Anebulo Pharmaceuticals?

Summary

How does Decoy Therapeutics compare to CalciMedica?

Summary

How does Decoy Therapeutics compare to Passage Bio?

Summary

How does Decoy Therapeutics compare to Natural Alternatives International?

Summary

How does Decoy Therapeutics compare to Cyclerion Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Decoy Therapeutics (DCOY) Competitors

DCOY vs. ANEB, CALC, PASG, NAII, and CYCN

How does Decoy Therapeutics compare to Anebulo Pharmaceuticals?

Do insiders and institutionals believe in DCOY or ANEB?

Which has preferable earnings & valuation, DCOY or ANEB?

Is DCOY or ANEB more profitable?

Do analysts rate DCOY or ANEB?

Which has more risk & volatility, DCOY or ANEB?

Does the media prefer DCOY or ANEB?

Summary

How does Decoy Therapeutics compare to CalciMedica?

Do insiders and institutionals believe in CALC or DCOY?

Is CALC or DCOY more profitable?

Do analysts prefer CALC or DCOY?

Which has more volatility & risk, CALC or DCOY?

Which has stronger valuation and earnings, CALC or DCOY?

Does the media favor CALC or DCOY?

Summary

How does Decoy Therapeutics compare to Passage Bio?

Does the media favor PASG or DCOY?

Which has more volatility and risk, PASG or DCOY?

Do insiders & institutionals hold more shares of PASG or DCOY?

Which has better valuation and earnings, PASG or DCOY?

Do analysts rate PASG or DCOY?

Is PASG or DCOY more profitable?

Summary

How does Decoy Therapeutics compare to Natural Alternatives International?

Is DCOY or NAII more profitable?

Does the media prefer DCOY or NAII?

Which has better valuation and earnings, DCOY or NAII?

Which has more volatility & risk, DCOY or NAII?

Do insiders and institutionals have more ownership in DCOY or NAII?

Do analysts rate DCOY or NAII?

Summary

How does Decoy Therapeutics compare to Cyclerion Therapeutics?

Is DCOY or CYCN more profitable?

Does the media prefer DCOY or CYCN?

Do analysts rate DCOY or CYCN?

Do institutionals and insiders hold more shares of DCOY or CYCN?

Which has stronger earnings and valuation, DCOY or CYCN?

Which has more risk & volatility, DCOY or CYCN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools